The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. METHODS: We conducted a randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at a dose of 5 mg twice daily, with placebo, in addition to standard antiplatelet therapy, in patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events. RESULTS: The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events. With a median follow-up of 241 days, the primary outcome of cardiovascular death, myocardial infarction, or ischemic stroke occurred in 279 of the 3705 patients (7.5%) assigned to apixaban (13.2 events per 100 patient-years) and in 293 of the 3687 patients (7.9%) assigned to placebo (14.0 events per 100 patient-years) (hazard ratio with apixaban, 0.95; 95% confidence interval [CI], 0.80 to 1.11; P=0.51). The primary safety outcome of major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) definition occurred in 46 of the 3673 patients (1.3%) who received at least one dose of apixaban (2.4 events per 100 patient-years) and in 18 of the 3642 patients (0.5%) who received at least one dose of placebo (0.9 events per 100 patient-years) (hazard ratio with apixaban, 2.59; 95% CI, 1.50 to 4.46; P=0.001). A greater number of intracranial and fatal bleeding events occurred with apixaban than with placebo. CONCLUSIONS: The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number, NCT00831441.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationCollaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Chesebro, J. H., Knatterud, G., Roberts, R., Borer, J., Cohen, L. S., Dalen, J., Dodge, H. T., Francis, C. K., Hillis, D., & Ludbrook, P. (1987) · Circulation · doi:10.1161/01.cir.76.1.142 · Cited by 2,244
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,853
Authors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,849
Self-citationFox, K. A. A., Dabbous, O. H., Goldberg, R. J., Pieper, K. S., Eagle, K. A., Van de Werf, F., Avezum, Á., Goodman, S. G., Flather, M. D., Anderson, F. A., et al. (2006) · BMJ · doi:10.1136/bmj.38985.646481.55 · Cited by 1,693
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., & White, H. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.011 · Cited by 1,618
Self-citationAnderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.013 · Cited by 1,510
Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855
Warfarin, Aspirin, or Both after Myocardial Infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020496 · Cited by 846
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Hornick, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62125-5 · Cited by 777
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775
Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement
Lassen, M. R., Raskob, G. E., Gallus, A., Pineo, G., Chen, D., & Portman, R. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810773 · Cited by 695
Mega, J., Braunwald, E., Mohanavelu, S., Burton, P., Poulter, R., Misselwitz, F., Hricak, V, Barnathan, E., Bordes, P., Witkowski, A., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60738-8 · Cited by 688
Sørensen, R., Hansen, M. L., Abildstrom, S. Z., Hvelplund, A., Andersson, C., Jørgensen, C., Madsen, J. K., Hansen, P. R., Køber, L., Torp-Pedersen, C., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61751-7 · Cited by 575
Bhatt, D. L., Roe, M. T., Peterson, E. D., Li, Y., Chen, A. Y., Harrington, R. A., Greenbaum, A. B., Berger, P. B., Cannon, C. P., Cohen, D. J., et al. (2004) · JAMA · doi:10.1001/jama.292.17.2096 · Cited by 568
Self-citationOldgren, J., Budaj, A., Granger, C. B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J. G. P., Van de Werf, F., Wallentin, L., & for the RE-DEEM Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr113 · Cited by 534
Self-citationUNIVERSAL DEFINITION OF MYOCARDIAL INFARCTION
Thygesen, K., Alpert, J., & White, H. (2008) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2008-4-5-91-105 · Cited by 525
Self-citationEarly versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes
Giugliano, R. P., White, J. A., Bode, C., Armstrong, P. W., Montalescot, G., Lewis, B. S., van `t Hof, A., Berdan, L. G., Lee, K. L., Strony, J. T., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901316 · Cited by 506
Self-citationFox, K. A. A., Carruthers, K. F., Dunbar, D. R., Graham, C., Manning, J. R., De Raedt, H., Buysschaert, I., Lambrechts, D., & Van de Werf, F. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq326 · Cited by 468
APPRAISE Steering Committee and Investigators (2009) · Circulation · doi:10.1161/circulationaha.108.832139 · Cited by 461
van Es, R. F., Jonker, J. J., Verheugt, F. W., Deckers, J. W., & Grobbee, D. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09409-6 · Cited by 423
Self-citationLASSEN, M. R., DAVIDSON, B. L., GALLUS, A., PINEO, G., ANSELL, J., & DEITCHMAN, D. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02764.x · Cited by 374
Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm
Bassand, J.-P. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm132 · Cited by 364
Rothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E., & Cook, J. R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00005 · Cited by 334
WONG, P. C., CRAIN, E. J., XIN, B., WEXLER, R. R., LAM, P. Y. S., PINTO, D. J., LUETTGEN, J. M., & KNABB, R. M. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02939.x · Cited by 300
Andreotti, F., Testa, L., Biondi-Zoccai, G. G. L., & Crea, F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi485 · Cited by 289
Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting
Karjalainen, P. P., Porela, P., Ylitalo, A., Vikman, S., Nyman, K., Vaittinen, M.-A., Airaksinen, T. J., Niemela, M., Vahlberg, T., & Airaksinen, K. E. J. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl488 · Cited by 286
Gibson, C. M., Mega, J. L., Burton, P. B. J., Goto, S., Verheugt, F. W. A., Bode, C., Plotnikov, A. N., Sun, X., Cook‐Bruns, N., & Braunwald, E. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.01.026 · Cited by 96
Self-citationPexelizumab and the APEX AMI Trial
Armstrong, P. W., & Granger, C. B. (2007) · JAMA · doi:10.1001/jama.297.17.1881-b · Cited by 69
Lewis, B. S., Mehta, S. R., Fox, K. A. A., Halon, D. A., Zhao, F., Peters, R. J. G., Keltai, M., Budaj, A., & Yusuf, S. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.01.044 · Cited by 69
Self-citation
Cited by
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citation2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes
Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., Funck-Brentano, C., Prescott, E., Storey, R. F., Deaton, C., Cuisset, T., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz425 · Cited by 7,166
Self-citationAuthors/Task Force Members, Steg, P. G., James, S. K., Atar, D., Badano, L. P., Lundqvist, C. B., Borger, M. A., Di Mario, C., Dickstein, K., Ducrocq, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs215 · Cited by 6,829
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Metadata
- Authors
- Alexander, J. H., Lopes, R. D., James, S., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S., Verheugt, F. W., Flather, M., Huber, K., Liaw, D., Husted, S. E., Lopez-Sendon, J., De Caterina, R., Jansky, P., Darius, H., Vinereanu, D., Cornel, J. H., Cools, F., Atar, D., Leiva-Pons, J. L., Keltai, M., Ogawa, H., Pais, P., Parkhomenko, A., Ruzyllo, W., Diaz, R., White, H., Ruda, M., Geraldes, M., Lawrence, J., Harrington, R. A., & Wallentin, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-08-25
- Volume
- 365
- Issue
- 8
- Pages
- 699-708
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108064339
- Cited by
- 1,005
- References
- 42
- FWCI
- 85.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.